In this study, we aimed at confirming the clinical usefulness of a supplementary additional
cyclosporin microemulsion preconcentrate (CyA
MEPC) administration in 15 patients with
psoriasis vulgaris whose disease activity had been unchanged or exacerbated with topical
maxacalcitol treatment. Each patient took a supplementary CyA
MEPC administration, 2.5 mg/kg per day in addition to
maxacalcitol ointment therapy. When the
Psoriasis Area and Severity Index (PASI) score revealed over a 75% decrease against the initial value, the administration of CyA
MEPC was tapered off, and a topical application of
maxacalcitol ointment was continued for the maintenance phase. All patients could obtain improvement within 12 weeks. In 12 patients whose PASI score reduced over 75%, CyA
MEPC was tapered off. Of those, five patients remained in remission by
maxacalcitol ointment for over 12 months and three patients for 6 months. In conclusion, this preliminary study may suggest that supplementary
therapy of short-term CyA
MEPC administration in combination with topical
vitamin D3 treatment may be worth trying for patients with moderate
psoriasis vulgaris.